Loading...
Cytosorbents Corp (CTSO) does not present a strong buy opportunity for a beginner, long-term investor at this time. While the company's financials show some improvement, the lack of significant trading trends, neutral insider and hedge fund activity, absence of recent news, and no strong proprietary trading signals suggest that the stock is not currently a compelling investment. The technical indicators are mixed, and the options data shows minimal activity, indicating low market interest. A 'hold' is recommended until more positive catalysts emerge.
The MACD histogram is positive and expanding, indicating a bullish trend. However, the RSI is at 79.9, which is in the neutral zone, and the moving averages are converging, suggesting no clear momentum. The stock is trading above the pivot point (0.672) but below the second resistance level (R2: 0.741). Overall, the technical indicators are mixed.

Revenue increased by 10.12% YoY, and gross margin improved significantly by 15.18% YoY in Q3 2025, indicating operational efficiency.
Net income remains negative at -$3.17M, and EPS has not improved YoY. There is no recent news, no significant insider or hedge fund activity, and no strong proprietary trading signals. Additionally, options activity is minimal, reflecting low market interest.
In Q3 2025, revenue increased to $9.49M (up 10.12% YoY), net income improved to -$3.17M (up 14.52% YoY), and gross margin increased to 70.28% (up 15.18% YoY). However, EPS remained unchanged at -0.05.
No data available for analyst ratings or price target changes.